Exagen (NASDAQ:XGN) PT Lowered to $7.00

Exagen (NASDAQ:XGNGet Rating) had its price objective dropped by equities research analysts at Canaccord Genuity Group from $8.00 to $7.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 105.88% from the stock’s previous close.

Separately, KeyCorp lowered Exagen from an “overweight” rating to a “sector weight” rating in a research report on Friday, August 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.75.

Exagen Trading Up 13.7 %

Shares of XGN opened at $3.40 on Tuesday. Exagen has a 52-week low of $2.10 and a 52-week high of $12.89. The business’s fifty day moving average is $2.98 and its 200-day moving average is $4.83. The company has a debt-to-equity ratio of 0.43, a quick ratio of 9.30 and a current ratio of 9.30. The firm has a market cap of $55.28 million, a price-to-earnings ratio of -1.50 and a beta of 1.17.

Institutional Investors Weigh In On Exagen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new stake in shares of Exagen in the 1st quarter valued at about $27,000. Intrust Bank NA bought a new stake in shares of Exagen in the 2nd quarter valued at about $57,000. First Bank & Trust grew its position in shares of Exagen by 47.1% in the 2nd quarter. First Bank & Trust now owns 23,176 shares of the company’s stock valued at $133,000 after buying an additional 7,423 shares during the last quarter. Advisors Capital Management LLC grew its position in shares of Exagen by 66.2% in the 3rd quarter. Advisors Capital Management LLC now owns 67,923 shares of the company’s stock valued at $143,000 after buying an additional 27,050 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in shares of Exagen by 7.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 25,731 shares of the company’s stock valued at $207,000 after buying an additional 1,839 shares during the last quarter. Institutional investors own 65.94% of the company’s stock.

Exagen Company Profile

(Get Rating)

Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Featured Articles

Analyst Recommendations for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.